This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis

This study has been terminated.
(Early termination of the study due to lack of efficacy.)
Sponsor:
Information provided by (Responsible Party):
MedImmune LLC
ClinicalTrials.gov Identifier:
NCT01629667
First received: June 12, 2012
Last updated: April 28, 2017
Last verified: April 2017
June 12, 2012
April 28, 2017
October 2012
May 2015   (Final data collection date for primary outcome measure)
Change From Baseline in Percent-predicted Forced Vital Capacity (FVC) at Week 52 [ Time Frame: Baseline and Week 52 ]
Forced vital capacity (FVC) is a standard pulmonary function test used to monitor disease progression in IPF. FVC was the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in litres. Predicted forced vital capacity is based on a formula using sex, age and height of a person, and is an estimate of healthy lung capacity. Percent of predicted FVC = (observed value)/(predicted value) * 100%.
Change from Baseline in Percent-Predicted Forced Vital Capacity at Week 72 [ Time Frame: Week 72 ]
Mean change from baseline in percent-predicted forced vital capacity
Complete list of historical versions of study NCT01629667 on ClinicalTrials.gov Archive Site
  • Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) [ Time Frame: From the start of study treatment through Week 88 ]
    Any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening situation (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect in the offspring of a participant who received Tralokinumab. Treatment-emergent were events between administration of investigational product and Week 88 that were absent before treatment or that worsened relative to pretreatment state.
  • Number of Participants With Clinical Laboratory Abnormalities Reported as Treatment-emergent Adverse Events [ Time Frame: From the start of study treatment through Week 88 ]
    An abnormal laboratory finding which required an action or intervention by the investigator, or a finding judged by the investigator to represent a change beyond the range of normal physiologic fluctuation were reported as an adverse event. Treatment-emergent were events between administration of investigational product and Week 88 that were absent before treatment or that worsened relative to pre-treatment state. Laboratory evaluations (haematology, serum chemistry and urinalysis) of blood and urine samples were performed.
  • Number of Participants With Vital Signs and Physical Findings Abnormalities Reported as Treatment-emergent Adverse Events [ Time Frame: From the start of study treatment through Week 88 ]
    Vital signs parameters included heart rate, blood pressure, temperature, weight, pulse oximetry and respiratory rate. Treatment-emergent were events between administration of investigational product and Week 88 that were absent before treatment or that worsened relative to pre-treatment state.
  • Number of Participants With Electrocardiogram Abnormalities Reported as Treatment-emergent Adverse Events [ Time Frame: From the start of study treatment through Week 88 ]
    AEs observed in participants with clinically significant ECG abnormalities were assessed. Tricuspid valve incompetence was the only abnormality reported as TEAE. ECG parameters included heart rate, PR, QRS, QT, and QTc intervals. Treatment-emergent were events between administration of investigational product and Week 88 that were absent before treatment or that worsened relative to pre-treatment state.
  • Percentage of Participants With Disease Progression [ Time Frame: Week 52 and 72 ]
    Progression-free Survival (PFS) was used to evaluate disease progression and the percentage of participants with disease progression. A participant was classified as having disease progression if at least one of the following criteria were met:• Adjudicated respiratory-related mortality. •Adjudicated hospitalization due to IPF exacerbation. •Confirmed decline in percent-predicted FVC of greater than or equal to (>=) 10%. •Confirmed decline in 6 minute walk test (6MWT) >= 50 meters.
  • Change From Baseline in Haemoglobin (Hb) Corrected Percent-predicted Diffusion Capacity for Carbon Monoxide (DLco) Through Week 72 [ Time Frame: Baseline, Week 52 and 72 ]
    The single breath technique was used to determine the DLco. The test was performed by qualified pulmonary function technicians with experience performing this study. Acceptable test criteria included:• An inspiratory volume of more than 85% of vital capacity. • A stable breath hold of 10 seconds (+/- 2 seconds) with no leaks, Valsalva or Mueller maneuvers. • Expiration in less than 4 seconds with appropriate clearance of dead space. The average of the two best acceptable maneuvers was used. There must be a minimum of 4 minutes between the performances of each test.
  • Change From Baseline in 6 Minute Walk Test (6MWT) Distance Through Week 72 [ Time Frame: Baseline, Week 52 and 72 ]
    The 6MWT measures the distance that a participant can walk on a measured, flat hard surface in a period of 6 minutes. The 6MWT evaluates the global and integrated responses of all body systems involved during walking.
  • Change From Baseline in Oxygen Saturation by Pulse Oximetry at Week 68 [ Time Frame: Baseline and Week 68 ]
    Participants transcutaneous oxygen saturation were observed by pulse oximetry.
  • Change From Baseline in Lung Volumes Through Week 72 [ Time Frame: Baseline, Week 52 and 72 ]
    Lung volumes were evaluated by total lung capacity (TLC), residual volume (RV), and vital capacity (VC). Lung volumes were determined by body plethysmography.
  • Percentage of Participants With Idiopathic Pulmonary Fibrosis (IPF) Exacerbations [ Time Frame: Week 52 and 72 ]

    The IPF exacerbations is defined as an acute, clinically significant, deterioration of unidentifiable cause in a participant with underlying IPF. Exacerbations of IPF were adjudicated according to the protocol definition by an independent committee as follows:

    1. Confirmed acute IPF exacerbation, 2. Suspected acute IPF exacerbation, 3. Not an IPF exacerbation with an alternative diagnosis provided if possible, and 4. Undetermined due to insufficient information.

  • Percentage of Participants With Adjudicated Mortality [ Time Frame: Week 52 and 72 ]
    Participants all cause mortality were observed. Events that resulted in participant death were adjudicated into respiratory-related mortality or all other cause mortality by an independent committee.
  • Percentage of Participants With Adjudicated Hospitalization [ Time Frame: Week 52 and 72 ]
    Participants who were hospitalized due to IPF exacerbation were observed. All events that resulted in the hospitalization of participants were adjudicated by an independent committee to determine if the event was due to an IPF exacerbation as follows: 1. Exacerbation or progression of IPF, 2. Result of a complication of IPF, 3. Not related to IPF (alternative diagnosis provided), and 4. Undetermined due to insufficient information.
  • Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Through Week 72 [ Time Frame: Baseline, Week 52 and 72 ]
    FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration.
  • Change From Baseline in Percent-predicted FEV1 Through Week 72 [ Time Frame: Baseline, Week 52 and 72 ]
    FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Predicted FEV1 is based on a formula using sex, age and height of a person, and is an estimate of healthy lung capacity. Percent of predicted FEV1 = (observed value)/(predicted value) * 100%.
  • Change From Baseline in Absolute Forced Vital Capacity (FVC) Through Week 72 [ Time Frame: Baseline, Week 52 and 72 ]
    Forced vital capacity (FVC) is a standard pulmonary function test used to monitor disease progression in IPF. FVC was the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in litres.
  • Number of Participants With Clinical Global Impression of Severity Scores [ Time Frame: Week 72 ]
    The CGI-S is a single, clinician completed, item designed to capture the clinician's impression of the participants IPF severity. Clinicians were asked to consider their experience in this participant population and rate the overall IPF severity of the participant using a 5-point scale (1 = very mild, 5 = very severe).
  • Number of Participants With Clinical Global Impression of Change Scores [ Time Frame: Week 72 ]
    The CGI-C is a single, clinician completed, item designed to capture the clinicians overall impression of change in IPF severity from the baseline state at Screening. Clinicians were asked to rate the participants IPF severity relative to their state at baseline using a 7-point scale (-3 = very much worse, 0 = no change, about the same, 3 = very much improved).
  • Change From Baseline in University of California San Diego Shortness of Breath Questionnaire (UCSD SOBQ) Total Score at Week 72 [ Time Frame: Baseline and Week 72 ]
    The UCSD SOBQ is a 24-item questionnaire designed to capture patient-reported shortness of breath. Respondents were asked to rate their breathlessness during 21 activities of daily living using a 6-point scale (0 = not at all breathless, 5 = maximally breathless or too breathless to do this activity). In addition to the 21 activity items, the UCSD SOBQ includes 3 additional questions about limitations due to shortness of breath, fear of harm from overexertion, and fear of shortness of breath. The UCSD SOBQ was scored by summing responses across all 24 items to form a total score. Scores range from 0-120 with higher scores indicative of greater shortness of breath.
  • Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score at Week 72 [ Time Frame: Baseline and Week 72 ]
    The SGRQ is a 50-item Patient-reported outcome (PRO) instrument developed to measure respiratory-related health status via 76 weighted responses. The SGRQ is divided into two parts. Part 1 asks respondents to consider the last 3 months and report on their respiratory symptoms using 5-point Likert scales. Part 2 asks respondents to consider their current state and respond to a series of dichotomous yes/no items related to their activities (activities that cause or were limited by breathlessness) and impacts (social functioning, psychological disturbances resulting from airways disease). Total scores and domain scores (symptoms, activities, and impact on daily life) were scored from 0-100, where lower scores indicate better health status.
  • Change From Baseline in Exacerbations of Chronic Pulmonary Disease (EXACT IPF) Total Score Through Week 72 [ Time Frame: Baseline, Week 52 and 72 ]
    The EXACT-IPF is a 14-item daily dairy used to capture the IPF related symptoms completed by the participants using an eDiary. The EXACT-IPF total score is the sum of all items ranged from 1 to 14. EXACT-IPF is an interval-level scale ranging from 0 to 100, where the higher scores indicate more severe condition. The EXACT-IPF used Likert scales (with 3 to 6 response options each) to capture participant reported IPF-related symptoms. The scores are the simple sum of item responses for each domain or single item.
  • Change From Baseline in European Quality of Life-5-Dimension 3 Level Version (EQ-5D-3L) (Including Visual Analog Scale [VAS]) at Week 72 [ Time Frame: Baseline and Week 72 ]
    The EQ-5D-3L is a standardized PRO used to capture respondent's general health status. The questionnaire assesses 5 dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 3 response options (no problem, some or moderate problems, and unable or extreme problems) that reflect increasing levels of difficulty. The questionnaire also includes a visual analog scale, where the participants were asked to rate their current health on a scale of 0-100, with 0 being the worst imaginable health state.
  • Number of Participants With Patient Global Impression of Severity (PGI-S) for Idiopathic Pulmonary Fibrosis (IPF) [ Time Frame: Week 72 ]
    The PGI-S is a single-item, global assessment of participant-perceived IPF severity. The assessment was designed to capture participant perceived IPF-related health status. Participants rate their IPF severity using a 5-point scale (1 = very mild, 5 = very severe).
  • Number of Participants With Patient Global Impression of Change (PGI-C) for Idiopathic Pulmonary Fibrosis (IPF) [ Time Frame: Week 72 ]
    The PGI-C is a single-item, global assessment designed to capture participant-perceived change in their IPF health condition using a 7-point scale (-3 = very much improved, 0 = no change, about the same, 3 = very much worse).
  • Mean Serum Concentration of Tralokinumab [ Time Frame: Predose, 0 hour, and 2 hour postdose on Week 0; predose on Week 4, 48, 72, 82 and 88 ]
    The mean serum concentration of Tralokinumab were observed.
  • Percentage of Participants Positive for Anti-Drug Antibodies to Tralokinumab [ Time Frame: From the start of study treatment through Week 88 ]
    A participant was considered ADA-positive across the study if they had a positive reading at any time point during the study.
  • Number of Participants with Adverse Events [ Time Frame: Day 1 - Week 84 ]
    Number and percent of subjects with at least one treatment-emergent adverse event
  • Number of Participants with Disease Progression [ Time Frame: Day 1 - Week 84 ]
    Number and percent of subjects who have documented disease progression
  • Mean Tralokinumab Serum Concentration [ Time Frame: Day 1 - Week 84 ]
    Mean serum concentration of tralokinumab
  • Number of Participants with Serious Adverse Events [ Time Frame: Day 1 - Week 84 ]
    Number and percent of subjects with at least one treatment-emergent serious adverse event
  • Number of Participants with Clinically Significant Electrocardiogram Abnormalities [ Time Frame: Day 1 - Week 84 ]
    Number and percent of subjects with at least one clinically significant electrocardiogram abnormality
  • Number of Participants with Clinically Significant Vital Sign Abnormalities [ Time Frame: Day 1 - Week 84 ]
    Number and percent of subjects with at least one clinically significant vital sign abnormality
  • Number of Participants with Clinically Significant Laboratory Abnormallities [ Time Frame: Day 1 - Week 84 ]
    Number and percent of subjects with at least one clinically significant laboratory abnormality
  • Change from Baseline in Diffusion Capacity for Carbon Monoxide at Weeks 36, 52, and 72 [ Time Frame: Weeks 36, 52, and 72 ]
    Mean change from baseline in percent-predicted diffusion capacity for carbon monoxide at Weeks 36, 52, and 72
  • Change from Baseline in Lung Volumes at Weeks 36, 52, and 72 [ Time Frame: Weeks 36, 52, and 72 ]
    Mean change from baseline in lung volumes (total lung capacity, residual volume, vital capacity, functional residual capacity, and inspiratory capacity) at Weeks 36, 52, and 72
  • Number of Participants with a Decline in the 6 Minute Walk Test [ Time Frame: Day 1 - Week 84 ]
    Number and percent of subjects with a decline in the 6 Minute Walk Test greater than or equal to 50 meters
  • Change from Baseline in Oxygen Saturation by Pulse Oximetry During the Study [ Time Frame: Day 1 - Week 84 ]
    Mean change from baseline in oxygen saturation by pulse oximetry
  • Number of Participants with Exacerbations of Idiopathic Pulmonary Fibrosis [ Time Frame: Day 1 - Week 84 ]
    Number and percent of subjects with at least one exacerbation of idiopathic pulmonary fibrosis
  • Change from Baseline in Lung Function During the Study [ Time Frame: Day 1 - Week 84 ]
    Mean change from baseline in lung function (forced expiratory volume in 1 second and forced vital capacity).
  • Mean Clinical Global Impression of Severity Scores [ Time Frame: Day 1 - Week 84 ]
    Mean Clinical Global Impression of Severity scores
  • Mean Clinical Global Impression of Change Scores [ Time Frame: Day 1 - Week 84 ]
    Mean Clinical Global Impression of Change score
  • Number of Participants with Positive Antibodies to Tralokinumab [ Time Frame: Day 1 - Week 84 ]
    Number and percent of subjects with positive antibodies to tralokinumab
Not Provided
Not Provided
 
A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
To study the safety and effectiveness of multiple-doses of tralokinumab on pulmonary function in adults with mild to moderate idiopathic pulmonary fibrosis (IPF). IPF is a chronic, progressive, irreversible, and usually fatal lung disease of unknown cause.
The primary objective of this study is to determine the effect of multiple doses of tralokinumab on pulmonary function in adults with mild to moderate IPF
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Investigator
Primary Purpose: Treatment
Idiopathic Pulmonary Fibrosis
  • Biological: Tralokinumab
    Participants will receive Tralokinumab 400 mg IV infusion Q4W for 68 Weeks.
  • Biological: Tralokinumab
    Participants will receive Tralokinumab 800 mg IV infusion Q4W for 68 Weeks.
  • Other: Placebo
    Participants will receive placebo IV once every 4 Weeks (Q4W) for 68 Weeks.
  • Experimental: Tralokinumab 400 milligram (mg)
    Participants will receive Tralokinumab 400 mg intravenous (IV) infusion Q4W for 68 Weeks.
    Intervention: Biological: Tralokinumab
  • Experimental: Tralokinumab 800 mg
    Participants will receive Tralokinumab 800 mg IV infusion Q4W for 68 Weeks.
    Intervention: Biological: Tralokinumab
  • Placebo Comparator: Placebo
    Participants will receive placebo IV once every 4 Weeks (Q4W) for 68 Weeks.
    Intervention: Other: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
409
January 2016
May 2015   (Final data collection date for primary outcome measure)

Key Inclusion Criteria:

  • 1) IPF diagnosis for <= 5 years prior to Visit 1 (screening). Confirmation of diagnosis of IPF in accordance is required for subject inclusion 2) Confirmed diagnosis of IPF by clinical characteristics, HRCT and surgical lung biopsy (if required) 3)Mild to moderate IPF to include all of the following at screening:

    1. FVC >= 50% predicted normal
    2. Partial pressure of oxygen in arterial blood (PaO2) of >= 55 mmHg on room air or 50 mmHg at high altitude (> 1500 meters), or oxygen saturation by pulse oximetry (SpO2) of >= 90%on room air at rest
    3. Hemoglobin-corrected diffusion capacity for carbon monoxide (DLCO) >= 30% predicted normal 4) Be able to walk >= 100 meters unassisted

Key Exclusion Criteria:

  1. A FEV1/FVC ratio less than 0.70 at the time of screening (postbronchodilator)
  2. The extent of emphysema on the HRCT is greater than the extent of fibrosis.
  3. Currently listed for lung transplantation
  4. Use of the following medications:

    1. Immunosuppressive medications (eg, methotrexate, cyclosporine, azathioprine, intramuscular long-acting depot corticosteroid) within 3 months prior to Visit 1 (screening). Oral prednisone <= 15 mg/day (or equivalent oral corticosteroid) is allowed for chronic use if subject was on a stable dose at least 30 days prior to Visit 1 (screening)
    2. Pirfenidone within 4 weeks prior to Visit 1 (screening)
    3. N-acetylcysteine within 4 weeks prior to Visit 1 (screening)
    4. Live attenuated vaccines within 4 weeks prior to Visit 1 (screening)
Sexes Eligible for Study: All
50 Years to 79 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Australia,   Canada,   Israel,   Korea, Republic of,   Peru,   United States
 
 
NCT01629667
CD-RI-CAT-354-1066
Yes
Not Provided
Not Provided
MedImmune LLC
MedImmune LLC
Not Provided
Study Director: Joseph Parker, MD MedImmune LLC
MedImmune LLC
April 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP